tiprankstipranks
Trending News
More News >
Nasus Pharma Ltd. (NSRX)
:NSRX
US Market

Nasus Pharma Ltd. (NSRX) Price & Analysis

Compare
3 Followers

NSRX Stock Chart & Stats

$7.67
--
Market closed
$7.67
--

Nasus Pharma Ltd. News

NSRX FAQ

What was Nasus Pharma Ltd.’s price range in the past 12 months?
Nasus Pharma Ltd. lowest stock price was $5.90 and its highest was $9.99 in the past 12 months.
    What is Nasus Pharma Ltd.’s market cap?
    Currently, no data Available
    When is Nasus Pharma Ltd.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Nasus Pharma Ltd.’s earnings last quarter?
    Currently, no data Available
    Is Nasus Pharma Ltd. overvalued?
    According to Wall Street analysts Nasus Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
      Does Nasus Pharma Ltd. pay dividends?
      Nasus Pharma Ltd. does not currently pay dividends.
      What is Nasus Pharma Ltd.’s EPS estimate?
      Nasus Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Nasus Pharma Ltd. have?
      Nasus Pharma Ltd. has 8,612,906 shares outstanding.
        What happened to Nasus Pharma Ltd.’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Nasus Pharma Ltd.?
        Currently, no hedge funds are holding shares in NSRX

        Company Description

        Nasus Pharma Ltd.

        Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.

        NSRX Stock 12 Month Forecast

        Average Price Target

        $22.00
        ▲(186.83% Upside)
        {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","11":"$11","15":"$15","19":"$19","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11,15,19,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.04,9.113846153846152,10.187692307692307,11.26153846153846,12.335384615384616,13.409230769230769,14.483076923076922,15.556923076923077,16.630769230769232,17.704615384615384,18.77846153846154,19.85230769230769,20.926153846153845,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.04,9.113846153846152,10.187692307692307,11.26153846153846,12.335384615384616,13.409230769230769,14.483076923076922,15.556923076923077,16.630769230769232,17.704615384615384,18.77846153846154,19.85230769230769,20.926153846153845,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.04,9.113846153846152,10.187692307692307,11.26153846153846,12.335384615384616,13.409230769230769,14.483076923076922,15.556923076923077,16.630769230769232,17.704615384615384,18.77846153846154,19.85230769230769,20.926153846153845,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.05,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.04,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
        Similar Stocks
        Company
        Price & Change
        Follow
        AIM ImmunoTech
        Scinai Immunotherapeutics
        Xenetic Biosciences
        Sensei Biotherapeutics
        GRI Bio
        Popular Stocks